The University of Chicago Header Logo

Connection

Louis Philipson to Diabetes Mellitus, Type 2

This is a "connection" page, showing publications Louis Philipson has written about Diabetes Mellitus, Type 2.
Connection Strength

5.507
  1. Approach to the Patient: Mitochondrial Diabetes: Contemporary Cases and a Precision Medicine Approach. J Clin Endocrinol Metab. 2026 Mar 17; 111(4):1175-1186.
    View in: PubMed
    Score: 0.507
  2. Obstructive Sleep Apnea, Resting Heart Rate, and Glycemic Variability in Adults With Maturity-Onset Diabetes of the Young. Diabetes. 2026 01 01; 75(1):215-222.
    View in: PubMed
    Score: 0.499
  3. Objective and Subjective Sleep Patterns in Adults With Maturity-Onset Diabetes of the Young (MODY). Diabetes Care. 2023 03 01; 46(3):608-612.
    View in: PubMed
    Score: 0.410
  4. Precision diabetes: Lessons learned from maturity-onset diabetes of the young (MODY). J Diabetes Investig. 2022 Sep; 13(9):1465-1471.
    View in: PubMed
    Score: 0.391
  5. Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab. 2021 01 01; 106(1):237-250.
    View in: PubMed
    Score: 0.353
  6. Harnessing heterogeneity in type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 02; 16(2):79-80.
    View in: PubMed
    Score: 0.331
  7. GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated. Acta Diabetol. 2016 Oct; 53(5):703-8.
    View in: PubMed
    Score: 0.255
  8. Resting beta-cells - A functional reserve? Diabetes Metab. 2016 Jun; 42(3):157-61.
    View in: PubMed
    Score: 0.251
  9. Genome wide association studies for diabetes: perspective on results and challenges. Pediatr Diabetes. 2013 Mar; 14(2):90-6.
    View in: PubMed
    Score: 0.204
  10. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf). 2011 Oct; 75(4):422-6.
    View in: PubMed
    Score: 0.186
  11. Glucose-induced ERM protein activation and translocation regulates insulin secretion. Am J Physiol Endocrinol Metab. 2010 Nov; 299(5):E772-85.
    View in: PubMed
    Score: 0.172
  12. Cold climate genes and the prevalence of type 2 diabetes mellitus. Med Hypotheses. 2006; 67(5):1034-41.
    View in: PubMed
    Score: 0.129
  13. Reactive species, cellular repair and risk factors in the onset of type 2 diabetes mellitus: review and hypothesis. Curr Diabetes Rev. 2006 May; 2(2):241-59.
    View in: PubMed
    Score: 0.128
  14. Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diabetes Obes Metab. 2006 Mar; 8(2):136-45.
    View in: PubMed
    Score: 0.126
  15. Oxidative reactive species in cell injury: Mechanisms in diabetes mellitus and therapeutic approaches. Ann N Y Acad Sci. 2005 Dec; 1066:136-51.
    View in: PubMed
    Score: 0.124
  16. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Ann Intern Med. 2023 04; 176(4):eL230007.
    View in: PubMed
    Score: 0.103
  17. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
    View in: PubMed
    Score: 0.100
  18. ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes. Diabetes Care. 2022 02 01; 45(2):261-266.
    View in: PubMed
    Score: 0.095
  19. Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. J Gen Intern Med. 2022 02; 37(2):439-448.
    View in: PubMed
    Score: 0.094
  20. The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med. 2022 02; 37(2):415-438.
    View in: PubMed
    Score: 0.093
  21. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obes Metab. 2020 11; 22(11):2045-2054.
    View in: PubMed
    Score: 0.086
  22. Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2). Diabetes. 2019 08; 68(8):1565-1576.
    View in: PubMed
    Score: 0.079
  23. GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants. Diabetes Res Clin Pract. 2019 May; 151:231-236.
    View in: PubMed
    Score: 0.079
  24. Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry. Acta Diabetol. 2019 Apr; 56(4):405-411.
    View in: PubMed
    Score: 0.077
  25. TCF1 links GIPR signaling to the control of beta cell function and survival. Nat Med. 2016 Jan; 22(1):84-90.
    View in: PubMed
    Score: 0.062
  26. Routine depression screening for patients with diabetes--reply. JAMA. 2014 Dec 10; 312(22):2413.
    View in: PubMed
    Score: 0.058
  27. The mental health comorbidities of diabetes. JAMA. 2014 Aug 20; 312(7):691-2.
    View in: PubMed
    Score: 0.057
  28. Insulin regulates carboxypeptidase E by modulating translation initiation scaffolding protein eIF4G1 in pancreatic ß cells. Proc Natl Acad Sci U S A. 2014 Jun 03; 111(22):E2319-28.
    View in: PubMed
    Score: 0.056
  29. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in ß cells. Cell Metab. 2014 Jan 07; 19(1):109-21.
    View in: PubMed
    Score: 0.054
  30. Lean versus obese diabetes mellitus patients in the United States minority population. J Diabetes Complications. 2014 Jul-Aug; 28(4):500-5.
    View in: PubMed
    Score: 0.054
  31. Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014; 37(1):202-9.
    View in: PubMed
    Score: 0.053
  32. A brief perspective on insulin production. Diabetes Obes Metab. 2009 Nov; 11 Suppl 4:189-96.
    View in: PubMed
    Score: 0.041
  33. Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice. Mol Cell Biol. 2009 Jun; 29(11):3151-62.
    View in: PubMed
    Score: 0.039
  34. When BAD is good for beta cells. Cell Metab. 2008 Apr; 7(4):280-1.
    View in: PubMed
    Score: 0.036
  35. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008 Apr; 57(4):1131-5.
    View in: PubMed
    Score: 0.036
  36. Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 09; 63(9):1671-1693.
    View in: PubMed
    Score: 0.022
  37. Integrated Pancreatic Blood Flow: Bidirectional Microcirculation Between Endocrine and Exocrine Pancreas. Diabetes. 2020 07; 69(7):1439-1450.
    View in: PubMed
    Score: 0.021
  38. Deletion of Protein Kinase D1 in Pancreatic ß-Cells Impairs Insulin Secretion in High-Fat Diet-Fed Mice. Diabetes. 2018 01; 67(1):71-77.
    View in: PubMed
    Score: 0.018
  39. NIDDM is associated with loss of pancreatic beta-cell L-type Ca2+ channel activity. Am J Physiol. 1996 Jan; 270(1 Pt 1):E133-40.
    View in: PubMed
    Score: 0.016
  40. Defective glucose-dependent endoplasmic reticulum Ca2+ sequestration in diabetic mouse islets of Langerhans. J Biol Chem. 1994 Jul 15; 269(28):18279-82.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.